NCT02706730View on ClinicalTrials.gov

A 6-Month Extension Study of OTO-104 in Meniere's Disease

PHASE3TerminatedINTERVENTIONAL

Enrollment

189

Participants

Timeline

Start Date

February 29, 2016

Primary Completion Date

September 30, 2017

Study Completion Date

September 30, 2017

Conditions

Meniere's Disease

Interventions

DRUG

OTO-104

Single intratympanic injection of 12 mg OTO-104

Trial Locations (1)

92121

Many sites in US. Refer to the contact info listed below., San Diego

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Otonomy, Inc.

INDUSTRY